Summit Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Summit Therapeutics Inc. (SMMT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2023-03-09
- Summit Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 0.00%.
- Summit Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.40%.
- Summit Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -3.90%.
- Summit Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was 26.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 11 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 11 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|---|---|
| 2022-12-31 | 0.00% 10-K · filed 2023-03-09 | |||
| 2021-12-31 | -0.40% 10-K · filed 2023-03-09 | |||
| 2020-12-31 | -3.90% 10-K/A · filed 2022-12-21 | |||
| 2019-12-31 | 1.20% 10-K · filed 2021-03-31 | -1.49% 8-K · filed 2020-09-29 | ||
| 2019-01-31 | 26.40% 10-K · filed 2021-03-31 | 25.93% 8-K · filed 2020-09-29 | ||
| 2018-01-31 | -1.60% 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |